No Data
No Data
List of unrestricted A-share shares of Zhitong | June 17.
On June 17th, a total of 32 listed companies had restricted stocks lifted, with a total market value of approximately 35.571 billion yuan. The specific situation of restricted stock lifting is as follows: Stock Code Stock Name Type of Restricted Shares Number of Lifting Shares Xiamen C&D Inc. 600153 Stock-based Incentive Restricted Circulation 9.5414 million Haohua Chemical Science & Technology Corp. 600378 Stock-based Incentive Restricted Circulation 6.8733 million ENN Natural Gas 600803 Stock-based Incentive Restricted Circulation 4.2525 million IDT Corp 002308 Stock-based Incentive Restricted Circulation 4.8495 million Aier Eye Hospital Group 300015 Stock-based Incentive Restricted Circulation 20.015 million
Baotou Dongbao Bio-tech (300239.SZ): 65,711,000 restricted shares will be lifted on June 17th.
On June 12th, Gelunhui reported that Baotou Dongbao Bio-tech (300239.SZ) issued a notice regarding the restricted shares of stocks to be released to specific investors. The number of restricted stocks to be lifted this time is 657.11022 million shares, accounting for 11.07% of the company's total share capital. The date of stock release is June 17, 2024 (Monday).
Here's What We Like About Baotou Dongbao Bio-TechLtd's (SZSE:300239) Upcoming Dividend
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) is about to go
Dongbao Biotech (300239.SZ) plans to pay 0.22 yuan for 10 shares to be deducted from interest on May 31
Dongbao Biotech (300239.SZ) announced that the company's 2023 dividend payment plan: for every 10 shares to all shareholders...
Fewer Investors Than Expected Jumping On Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239)
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 32x, you may consider Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) as an attractive investment with its 28.4
Dongbao Biotech (300239.SZ): Net profit of 259.615 million yuan in the first quarter decreased 16.62% year-on-year
Gelonghui, April 23 | Dongbao Biotech (300239.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 242 million yuan, down 7.48% year on year; net profit attributable to shareholders of listed companies was 25.9615 million yuan, down 16.62% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 236.22,300 yuan, down 21.61% year on year; basic earnings per share were 0.0437 yuan.
No Data